U.S. Markets closed
  • S&P Futures

    3,667.25
    0.00 (0.00%)
     
  • Dow Futures

    29,858.00
    -10.00 (-0.03%)
     
  • Nasdaq Futures

    12,471.25
    +17.00 (+0.14%)
     
  • Russell 2000 Futures

    1,837.90
    +0.40 (+0.02%)
     
  • Crude Oil

    45.10
    -0.18 (-0.40%)
     
  • Gold

    1,830.60
    +0.40 (+0.02%)
     
  • Silver

    24.01
    -0.07 (-0.29%)
     
  • EUR/USD

    1.2118
    +0.0003 (+0.0242%)
     
  • 10-Yr Bond

    0.9480
    +0.0140 (+1.50%)
     
  • Vix

    21.17
    +0.40 (+1.93%)
     
  • GBP/USD

    1.3372
    -0.0004 (-0.0308%)
     
  • USD/JPY

    104.4740
    +0.0500 (+0.0479%)
     
  • BTC-USD

    19,066.83
    +35.55 (+0.19%)
     
  • CMC Crypto 200

    373.99
    +9.07 (+2.49%)
     
  • FTSE 100

    6,463.39
    +78.66 (+1.23%)
     
  • Nikkei 225

    26,816.57
    +15.59 (+0.06%)
     

If You Had Bought Concert Pharmaceuticals (NASDAQ:CNCE) Stock A Year Ago, You Could Pocket A 59% Gain Today

Simply Wall St
·2 min read

The Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) share price has had a bad week, falling 13%. While that might be a setback, it doesn't negate the nice returns received over the last twelve months. To wit, it had solidly beat the market, up 59%.

View our latest analysis for Concert Pharmaceuticals

Concert Pharmaceuticals isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. When a company doesn't make profits, we'd generally expect to see good revenue growth. As you can imagine, fast revenue growth, when maintained, often leads to fast profit growth.

Concert Pharmaceuticals grew its revenue by 495% last year. That's well above most other pre-profit companies. While the share price gain of 59% over twelve months is pretty tasty, you might argue it doesn't fully reflect the strong revenue growth. If that's the case, now might be the time to take a close look at Concert Pharmaceuticals. Human beings have trouble conceptualizing (and valuing) exponential growth. Is that what we're seeing here?

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

earnings-and-revenue-growth
earnings-and-revenue-growth

If you are thinking of buying or selling Concert Pharmaceuticals stock, you should check out this FREE detailed report on its balance sheet.

A Different Perspective

It's nice to see that Concert Pharmaceuticals shareholders have received a total shareholder return of 59% over the last year. That certainly beats the loss of about 9% per year over the last half decade. This makes us a little wary, but the business might have turned around its fortunes. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. For instance, we've identified 2 warning signs for Concert Pharmaceuticals that you should be aware of.

Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of companies we expect will grow earnings.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com.